title: An experimental study of dendritic cells transfected with cancer stem-like cells RNA against 9L brain tumors.
abstract: Cancer stem cells are defined as a subpopulation of cancer cells with the capacity to self-renew and differentiate, which may play critical roles in tumor initiation, progress and resistance to current treatments. It has been reported that Dendritic cells (DCs) transfected with total tumor RNA could induce strong antitumor T-cell responses both in vivo and in vitro. In the study, we investigated the characteristics of 9L tumor spheres, and evaluated the antitumor effects of DCs transfected with 9L tumor spheres RNA in vivo. The results showed that 9L tumor spheres have the properties of cancer stem cells, and the majority of 9L cells were positive for CD133 and nestin. DCs transfected with 9L tumor spheres RNA can significantly inhibit glioma growth and prolong the survival of 9L glioma-bearing rats. These results demonstrated that 9L cancer stem like cells were enriched in tumor spheres, and they were a part of CD133+ cells, DCs transfected with cancer stem cells RNA may be an effective therapy for glioma.
authors.affiliation: Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
authors.forename: Zong-yu
authors.initials: ZY
authors.lastname: Xiao
authors.forename: Hao
authors.initials: H
authors.lastname: Tang
authors.forename: Zhi-min
authors.initials: ZM
authors.lastname: Xu
authors.forename: Zhong-jie
authors.initials: ZJ
authors.lastname: Yan
authors.forename: Peng
authors.initials: P
authors.lastname: Li
authors.forename: Ying-qian
authors.initials: YQ
authors.lastname: Cai
authors.forename: Xiao-dan
authors.initials: XD
authors.lastname: Jiang
authors.forename: Ru-xiang
authors.initials: RX
authors.lastname: Xu
mesh_terms: D000071916:AC133 Antigen; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D019496:Cancer Vaccines / Q000235:genetics* / Q000627:therapeutic use; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D003470:Culture Media; D003713:Dendritic Cells / Q000378:metabolism / Q000637:transplantation*; D004815:Epidermal Growth Factor / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D018316:Gliosarcoma / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D006023:Glycoproteins / Q000378:metabolism; D007371:Interferon-gamma / Q000097:blood; D007381:Intermediate Filament Proteins / Q000378:metabolism; D053208:Kaplan-Meier Estimate; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology*; D009419:Nerve Tissue Proteins / Q000378:metabolism; D064231:Nestin; D010455:Peptides / Q000378:metabolism; D012313:RNA / Q000276:immunology*; D051381:Rats; D014162:Transfection; D023041:Xenograft Model Antitumor Assays
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D019496:Cancer Vaccines; D003470:Culture Media; D006023:Glycoproteins; D007381:Intermediate Filament Proteins; D009419:Nerve Tissue Proteins; C577486:Nes protein, rat; D064231:Nestin; D010455:Peptides; C000606025:Prom1 protein, rat; D016222:Fibroblast Growth Factor 2; D004815:Epidermal Growth Factor; D012313:RNA; D007371:Interferon-gamma